microdosing glp 1 agonists Benefits of GLP-1 GLP-1 (glucagon-like peptide-1) receptor agonists, such as tirzepatide (Zepbound) or semaglutide (Ozempic, Wegovy), are typically prescribed for diabetes and obesity management at standard therapeutic doses. Microdosing Microdosing of GLP-1's / Wellness

The table below shows common similar side effects of Ozempic as well as Mounjaro 7 , 8 : Other rare but serious side effects of both these medications include: Also, semaglutide has been linked to a higher risk of worsening diabetic retinopathy 15

doi:10.1056/NEJMoa2028395 201

111 IKK/NF-B-mediated impairment 112 and -aminobutyric acid and glutamate transporter systems 113 may also be involved in diabetes-induced damage of neurogenesis

Coding Best Practices for GLP-1 Claims Always verify payer coverage policies Confirm FDA-approved indication Use the most specific ICD-10 code Include BMI codes when required Ensure documentation supports medical necessity Confirm whether the drug is pharmacy or medical benefit Avoid unclassified J-codes unless required Track prior authorization approvals Document patient counseling and monitoring Watch for Medicare weight-loss exclusions Denial Prevention Checklist Before submitting GLP-1-related claims, confirm: Correct diagnosis code selection BMI documented and coded PA approval on file Proper benefit type (pharmacy vs medical) E/M level supported by documentation Drug coverage confirmed by payer GLP-1 medications are transforming diabetes and obesity care, but they bring complex billing and compliance challenges

Diabetes Care 28, 10921100

doi: 10.1016/S0021-9258(19)36565-2 87 YoungAAGedulinBRBhavsarSBodkinNJodkaCHansenBet al